nodes	percent_of_prediction	percent_of_DWPC	metapath
Triamcinolone—NR3C1—Medroxyprogesterone Acetate—uterine cancer	0.165	0.46	CbGbCtD
Triamcinolone—NR3C1—Progesterone—uterine cancer	0.109	0.305	CbGbCtD
Triamcinolone—Prednicarbate—Medroxyprogesterone Acetate—uterine cancer	0.0563	0.112	CrCrCtD
Triamcinolone—Fluoxymesterone—Medroxyprogesterone Acetate—uterine cancer	0.0517	0.103	CrCrCtD
Triamcinolone—Fludrocortisone—Medroxyprogesterone Acetate—uterine cancer	0.0504	0.101	CrCrCtD
Triamcinolone—Testolactone—Progesterone—uterine cancer	0.0491	0.0979	CrCrCtD
Triamcinolone—Fluorometholone—Medroxyprogesterone Acetate—uterine cancer	0.0468	0.0934	CrCrCtD
Triamcinolone—Fluoxymesterone—Progesterone—uterine cancer	0.0451	0.09	CrCrCtD
Triamcinolone—Fludrocortisone—Progesterone—uterine cancer	0.0439	0.0876	CrCrCtD
Triamcinolone—Methylprednisolone—Medroxyprogesterone Acetate—uterine cancer	0.0437	0.0873	CrCrCtD
Triamcinolone—Hydrocortisone—Medroxyprogesterone Acetate—uterine cancer	0.0411	0.082	CrCrCtD
Triamcinolone—Prednisolone—Progesterone—uterine cancer	0.0373	0.0745	CrCrCtD
Triamcinolone—Hydrocortisone—Progesterone—uterine cancer	0.0358	0.0715	CrCrCtD
Triamcinolone—PTGS2—Etoposide—uterine cancer	0.0345	0.0963	CbGbCtD
Triamcinolone—CYP3A4—Medroxyprogesterone Acetate—uterine cancer	0.023	0.0642	CbGbCtD
Triamcinolone—CYP3A4—Progesterone—uterine cancer	0.0153	0.0425	CbGbCtD
Triamcinolone—CYP3A4—Etoposide—uterine cancer	0.00683	0.019	CbGbCtD
Triamcinolone—SERPINA6—oviduct—uterine cancer	0.00496	0.205	CbGeAlD
Triamcinolone—CYP3A4—Doxorubicin—uterine cancer	0.00466	0.013	CbGbCtD
Triamcinolone—PTGS2—artery—uterine cancer	0.00124	0.0514	CbGeAlD
Triamcinolone—SERPINA6—renal system—uterine cancer	0.00115	0.0477	CbGeAlD
Triamcinolone—SERPINA6—female reproductive system—uterine cancer	0.000924	0.0382	CbGeAlD
Triamcinolone—BCHE—myometrium—uterine cancer	0.00078	0.0322	CbGeAlD
Triamcinolone—NR3C1—myometrium—uterine cancer	0.000694	0.0287	CbGeAlD
Triamcinolone—BCHE—uterine cervix—uterine cancer	0.000607	0.0251	CbGeAlD
Triamcinolone—PTGS2—myometrium—uterine cancer	0.000601	0.0248	CbGeAlD
Triamcinolone—BCHE—smooth muscle tissue—uterine cancer	0.00059	0.0244	CbGeAlD
Triamcinolone—Testolactone—CYP19A1—uterine cancer	0.000551	0.247	CrCbGaD
Triamcinolone—BCHE—endometrium—uterine cancer	0.000549	0.0227	CbGeAlD
Triamcinolone—NR3C1—epithelium—uterine cancer	0.000545	0.0225	CbGeAlD
Triamcinolone—NR3C1—uterine cervix—uterine cancer	0.00054	0.0223	CbGeAlD
Triamcinolone—BCHE—mammalian vulva—uterine cancer	0.000531	0.0219	CbGeAlD
Triamcinolone—NR3C1—smooth muscle tissue—uterine cancer	0.000525	0.0217	CbGeAlD
Triamcinolone—NR3C1—decidua—uterine cancer	0.000515	0.0213	CbGeAlD
Triamcinolone—BCHE—uterus—uterine cancer	0.000506	0.0209	CbGeAlD
Triamcinolone—NR3C1—renal system—uterine cancer	0.000506	0.0209	CbGeAlD
Triamcinolone—NR3C1—endometrium—uterine cancer	0.000489	0.0202	CbGeAlD
Triamcinolone—NR3C1—mammalian vulva—uterine cancer	0.000473	0.0195	CbGeAlD
Triamcinolone—PTGS2—epithelium—uterine cancer	0.000472	0.0195	CbGeAlD
Triamcinolone—PTGS2—uterine cervix—uterine cancer	0.000468	0.0193	CbGeAlD
Triamcinolone—BCHE—female reproductive system—uterine cancer	0.000455	0.0188	CbGeAlD
Triamcinolone—PTGS2—smooth muscle tissue—uterine cancer	0.000455	0.0188	CbGeAlD
Triamcinolone—NR3C1—uterus—uterine cancer	0.00045	0.0186	CbGeAlD
Triamcinolone—PTGS2—renal system—uterine cancer	0.000438	0.0181	CbGeAlD
Triamcinolone—PTGS2—endometrium—uterine cancer	0.000423	0.0175	CbGeAlD
Triamcinolone—BCHE—vagina—uterine cancer	0.000411	0.017	CbGeAlD
Triamcinolone—NR3C1—female reproductive system—uterine cancer	0.000405	0.0167	CbGeAlD
Triamcinolone—PTGS2—uterus—uterine cancer	0.00039	0.0161	CbGeAlD
Triamcinolone—CYP3A4—renal system—uterine cancer	0.000382	0.0158	CbGeAlD
Triamcinolone—NR3C1—female gonad—uterine cancer	0.000368	0.0152	CbGeAlD
Triamcinolone—NR3C1—vagina—uterine cancer	0.000366	0.0151	CbGeAlD
Triamcinolone—PTGS2—female reproductive system—uterine cancer	0.00035	0.0145	CbGeAlD
Triamcinolone—Fluticasone Propionate—PGR—uterine cancer	0.000344	0.154	CrCbGaD
Triamcinolone—PTGS2—female gonad—uterine cancer	0.000319	0.0132	CbGeAlD
Triamcinolone—PTGS2—vagina—uterine cancer	0.000317	0.0131	CbGeAlD
Triamcinolone—Betamethasone—PGR—uterine cancer	0.000315	0.141	CrCbGaD
Triamcinolone—CYP3A4—female reproductive system—uterine cancer	0.000306	0.0126	CbGeAlD
Triamcinolone—BCHE—lymph node—uterine cancer	0.000266	0.011	CbGeAlD
Triamcinolone—Fluoxymesterone—ESR1—uterine cancer	0.000255	0.114	CrCbGaD
Triamcinolone—Dexamethasone—CYP11A1—uterine cancer	0.000243	0.109	CrCbGaD
Triamcinolone—NR3C1—lymph node—uterine cancer	0.000237	0.00978	CbGeAlD
Triamcinolone—Betamethasone—CYP19A1—uterine cancer	0.000216	0.0968	CrCbGaD
Triamcinolone—PTGS2—lymph node—uterine cancer	0.000205	0.00847	CbGeAlD
Triamcinolone—Insomnia—Progesterone—uterine cancer	0.000201	0.00184	CcSEcCtD
Triamcinolone—Petechiae—Doxorubicin—uterine cancer	0.000201	0.00184	CcSEcCtD
Triamcinolone—Infection—Medroxyprogesterone Acetate—uterine cancer	0.0002	0.00183	CcSEcCtD
Triamcinolone—Paraesthesia—Progesterone—uterine cancer	0.000199	0.00183	CcSEcCtD
Triamcinolone—Dyspnoea—Progesterone—uterine cancer	0.000198	0.00181	CcSEcCtD
Triamcinolone—Shock—Medroxyprogesterone Acetate—uterine cancer	0.000198	0.00181	CcSEcCtD
Triamcinolone—Tachycardia—Medroxyprogesterone Acetate—uterine cancer	0.000196	0.0018	CcSEcCtD
Triamcinolone—Arthropathy—Epirubicin—uterine cancer	0.000196	0.0018	CcSEcCtD
Triamcinolone—Dyspepsia—Progesterone—uterine cancer	0.000195	0.00179	CcSEcCtD
Triamcinolone—Cough increased—Epirubicin—uterine cancer	0.000195	0.00179	CcSEcCtD
Triamcinolone—Sweating increased—Etoposide—uterine cancer	0.000195	0.00178	CcSEcCtD
Triamcinolone—Hyperhidrosis—Medroxyprogesterone Acetate—uterine cancer	0.000194	0.00178	CcSEcCtD
Triamcinolone—Erythema—Dactinomycin—uterine cancer	0.000192	0.00176	CcSEcCtD
Triamcinolone—Fatigue—Progesterone—uterine cancer	0.000191	0.00175	CcSEcCtD
Triamcinolone—PTGS2—Quercetin and Nf-kB/ AP-1 Induced Cell Apoptosis—NFE2L2—uterine cancer	0.000191	0.0414	CbGpPWpGaD
Triamcinolone—Pain—Progesterone—uterine cancer	0.00019	0.00174	CcSEcCtD
Triamcinolone—Ulcer—Epirubicin—uterine cancer	0.000189	0.00173	CcSEcCtD
Triamcinolone—Dexamethasone—PGR—uterine cancer	0.000183	0.0821	CrCbGaD
Triamcinolone—Musculoskeletal discomfort—Medroxyprogesterone Acetate—uterine cancer	0.000183	0.00168	CcSEcCtD
Triamcinolone—Feeling abnormal—Progesterone—uterine cancer	0.000183	0.00168	CcSEcCtD
Triamcinolone—Insomnia—Medroxyprogesterone Acetate—uterine cancer	0.000182	0.00167	CcSEcCtD
Triamcinolone—Arthropathy—Doxorubicin—uterine cancer	0.000182	0.00166	CcSEcCtD
Triamcinolone—Paraesthesia—Medroxyprogesterone Acetate—uterine cancer	0.000181	0.00166	CcSEcCtD
Triamcinolone—Cough increased—Doxorubicin—uterine cancer	0.00018	0.00165	CcSEcCtD
Triamcinolone—Dyspnoea—Medroxyprogesterone Acetate—uterine cancer	0.000179	0.00164	CcSEcCtD
Triamcinolone—Hiccups—Epirubicin—uterine cancer	0.000178	0.00164	CcSEcCtD
Triamcinolone—Ill-defined disorder—Dactinomycin—uterine cancer	0.000178	0.00164	CcSEcCtD
Triamcinolone—PTGS2—Synthesis of Prostaglandins (PG) and Thromboxanes (TX)—AKR1C3—uterine cancer	0.000178	0.0386	CbGpPWpGaD
Triamcinolone—Dyspepsia—Medroxyprogesterone Acetate—uterine cancer	0.000177	0.00162	CcSEcCtD
Triamcinolone—Urticaria—Progesterone—uterine cancer	0.000176	0.00162	CcSEcCtD
Triamcinolone—Dermatitis contact—Epirubicin—uterine cancer	0.000176	0.00162	CcSEcCtD
Triamcinolone—Acute coronary syndrome—Etoposide—uterine cancer	0.000176	0.00161	CcSEcCtD
Triamcinolone—Body temperature increased—Progesterone—uterine cancer	0.000175	0.00161	CcSEcCtD
Triamcinolone—Ulcer—Doxorubicin—uterine cancer	0.000175	0.0016	CcSEcCtD
Triamcinolone—Myocardial infarction—Etoposide—uterine cancer	0.000175	0.0016	CcSEcCtD
Triamcinolone—Neuropathy peripheral—Etoposide—uterine cancer	0.000175	0.0016	CcSEcCtD
Triamcinolone—Fatigue—Medroxyprogesterone Acetate—uterine cancer	0.000173	0.00159	CcSEcCtD
Triamcinolone—Malaise—Dactinomycin—uterine cancer	0.000173	0.00159	CcSEcCtD
Triamcinolone—Candida infection—Epirubicin—uterine cancer	0.00017	0.00156	CcSEcCtD
Triamcinolone—Skin exfoliation—Epirubicin—uterine cancer	0.00017	0.00156	CcSEcCtD
Triamcinolone—Fluid retention—Epirubicin—uterine cancer	0.000169	0.00155	CcSEcCtD
Triamcinolone—Neuropathy—Epirubicin—uterine cancer	0.000168	0.00154	CcSEcCtD
Triamcinolone—Feeling abnormal—Medroxyprogesterone Acetate—uterine cancer	0.000166	0.00152	CcSEcCtD
Triamcinolone—Hiccups—Doxorubicin—uterine cancer	0.000165	0.00151	CcSEcCtD
Triamcinolone—Myalgia—Dactinomycin—uterine cancer	0.000164	0.0015	CcSEcCtD
Triamcinolone—Hypersensitivity—Progesterone—uterine cancer	0.000164	0.0015	CcSEcCtD
Triamcinolone—Dermatitis contact—Doxorubicin—uterine cancer	0.000163	0.0015	CcSEcCtD
Triamcinolone—Discomfort—Dactinomycin—uterine cancer	0.000162	0.00148	CcSEcCtD
Triamcinolone—Ecchymosis—Epirubicin—uterine cancer	0.000161	0.00148	CcSEcCtD
Triamcinolone—Urticaria—Medroxyprogesterone Acetate—uterine cancer	0.00016	0.00146	CcSEcCtD
Triamcinolone—Asthenia—Progesterone—uterine cancer	0.000159	0.00146	CcSEcCtD
Triamcinolone—Body temperature increased—Medroxyprogesterone Acetate—uterine cancer	0.000159	0.00146	CcSEcCtD
Triamcinolone—Pulmonary oedema—Epirubicin—uterine cancer	0.000159	0.00146	CcSEcCtD
Triamcinolone—Candida infection—Doxorubicin—uterine cancer	0.000158	0.00144	CcSEcCtD
Triamcinolone—Skin exfoliation—Doxorubicin—uterine cancer	0.000158	0.00144	CcSEcCtD
Triamcinolone—Pruritus—Progesterone—uterine cancer	0.000157	0.00144	CcSEcCtD
Triamcinolone—Oedema—Dactinomycin—uterine cancer	0.000157	0.00144	CcSEcCtD
Triamcinolone—Fluid retention—Doxorubicin—uterine cancer	0.000157	0.00144	CcSEcCtD
Triamcinolone—Infection—Dactinomycin—uterine cancer	0.000156	0.00143	CcSEcCtD
Triamcinolone—Neuropathy—Doxorubicin—uterine cancer	0.000155	0.00142	CcSEcCtD
Triamcinolone—Thrombophlebitis—Epirubicin—uterine cancer	0.00015	0.00137	CcSEcCtD
Triamcinolone—Ecchymosis—Doxorubicin—uterine cancer	0.000149	0.00137	CcSEcCtD
Triamcinolone—Diabetes mellitus—Epirubicin—uterine cancer	0.000149	0.00136	CcSEcCtD
Triamcinolone—Hypersensitivity—Medroxyprogesterone Acetate—uterine cancer	0.000148	0.00136	CcSEcCtD
Triamcinolone—Pulmonary oedema—Doxorubicin—uterine cancer	0.000147	0.00135	CcSEcCtD
Triamcinolone—Dizziness—Progesterone—uterine cancer	0.000147	0.00135	CcSEcCtD
Triamcinolone—Vascular purpura—Epirubicin—uterine cancer	0.000145	0.00133	CcSEcCtD
Triamcinolone—Asthenia—Medroxyprogesterone Acetate—uterine cancer	0.000144	0.00132	CcSEcCtD
Triamcinolone—CYP3A4—Benzo(a)pyrene metabolism—AKR1C1—uterine cancer	0.000143	0.0312	CbGpPWpGaD
Triamcinolone—Musculoskeletal discomfort—Dactinomycin—uterine cancer	0.000143	0.00131	CcSEcCtD
Triamcinolone—Cardiac failure congestive—Epirubicin—uterine cancer	0.000143	0.00131	CcSEcCtD
Triamcinolone—Pruritus—Medroxyprogesterone Acetate—uterine cancer	0.000142	0.0013	CcSEcCtD
Triamcinolone—Vomiting—Progesterone—uterine cancer	0.000141	0.00129	CcSEcCtD
Triamcinolone—Rash—Progesterone—uterine cancer	0.00014	0.00128	CcSEcCtD
Triamcinolone—Dermatitis—Progesterone—uterine cancer	0.00014	0.00128	CcSEcCtD
Triamcinolone—Headache—Progesterone—uterine cancer	0.000139	0.00127	CcSEcCtD
Triamcinolone—Thrombophlebitis—Doxorubicin—uterine cancer	0.000138	0.00127	CcSEcCtD
Triamcinolone—Increased appetite—Epirubicin—uterine cancer	0.000138	0.00126	CcSEcCtD
Triamcinolone—Diabetes mellitus—Doxorubicin—uterine cancer	0.000138	0.00126	CcSEcCtD
Triamcinolone—Dysgeusia—Etoposide—uterine cancer	0.000136	0.00125	CcSEcCtD
Triamcinolone—Dermatitis bullous—Epirubicin—uterine cancer	0.000136	0.00124	CcSEcCtD
Triamcinolone—Fatigue—Dactinomycin—uterine cancer	0.000135	0.00124	CcSEcCtD
Triamcinolone—Back pain—Etoposide—uterine cancer	0.000135	0.00123	CcSEcCtD
Triamcinolone—Purpura—Epirubicin—uterine cancer	0.000134	0.00123	CcSEcCtD
Triamcinolone—Pain—Dactinomycin—uterine cancer	0.000134	0.00123	CcSEcCtD
Triamcinolone—Vascular purpura—Doxorubicin—uterine cancer	0.000134	0.00123	CcSEcCtD
Triamcinolone—Anaphylactoid reaction—Epirubicin—uterine cancer	0.000134	0.00123	CcSEcCtD
Triamcinolone—Dizziness—Medroxyprogesterone Acetate—uterine cancer	0.000133	0.00122	CcSEcCtD
Triamcinolone—Cardiac failure congestive—Doxorubicin—uterine cancer	0.000132	0.00121	CcSEcCtD
Triamcinolone—Nausea—Progesterone—uterine cancer	0.000132	0.00121	CcSEcCtD
Triamcinolone—Osteoarthritis—Epirubicin—uterine cancer	0.00013	0.00119	CcSEcCtD
Triamcinolone—Feeling abnormal—Dactinomycin—uterine cancer	0.000129	0.00119	CcSEcCtD
Triamcinolone—Ill-defined disorder—Etoposide—uterine cancer	0.000129	0.00118	CcSEcCtD
Triamcinolone—Vomiting—Medroxyprogesterone Acetate—uterine cancer	0.000128	0.00117	CcSEcCtD
Triamcinolone—Increased appetite—Doxorubicin—uterine cancer	0.000128	0.00117	CcSEcCtD
Triamcinolone—Affect lability—Epirubicin—uterine cancer	0.000127	0.00117	CcSEcCtD
Triamcinolone—Rash—Medroxyprogesterone Acetate—uterine cancer	0.000127	0.00116	CcSEcCtD
Triamcinolone—Dermatitis—Medroxyprogesterone Acetate—uterine cancer	0.000127	0.00116	CcSEcCtD
Triamcinolone—Headache—Medroxyprogesterone Acetate—uterine cancer	0.000126	0.00116	CcSEcCtD
Triamcinolone—Dexamethasone—CYP19A1—uterine cancer	0.000126	0.0563	CrCbGaD
Triamcinolone—Malaise—Etoposide—uterine cancer	0.000125	0.00115	CcSEcCtD
Triamcinolone—Dermatitis bullous—Doxorubicin—uterine cancer	0.000125	0.00115	CcSEcCtD
Triamcinolone—Vertigo—Etoposide—uterine cancer	0.000125	0.00115	CcSEcCtD
Triamcinolone—Purpura—Doxorubicin—uterine cancer	0.000124	0.00114	CcSEcCtD
Triamcinolone—Body temperature increased—Dactinomycin—uterine cancer	0.000124	0.00114	CcSEcCtD
Triamcinolone—Anaphylactoid reaction—Doxorubicin—uterine cancer	0.000124	0.00114	CcSEcCtD
Triamcinolone—Cardiac arrest—Epirubicin—uterine cancer	0.000123	0.00113	CcSEcCtD
Triamcinolone—Mood swings—Epirubicin—uterine cancer	0.000123	0.00112	CcSEcCtD
Triamcinolone—Loss of consciousness—Etoposide—uterine cancer	0.000122	0.00112	CcSEcCtD
Triamcinolone—Cough—Etoposide—uterine cancer	0.000121	0.00111	CcSEcCtD
Triamcinolone—Convulsion—Etoposide—uterine cancer	0.000121	0.00111	CcSEcCtD
Triamcinolone—Hypertension—Etoposide—uterine cancer	0.00012	0.0011	CcSEcCtD
Triamcinolone—Osteoarthritis—Doxorubicin—uterine cancer	0.00012	0.0011	CcSEcCtD
Triamcinolone—Nausea—Medroxyprogesterone Acetate—uterine cancer	0.000119	0.0011	CcSEcCtD
Triamcinolone—Affect lability—Doxorubicin—uterine cancer	0.000118	0.00108	CcSEcCtD
Triamcinolone—Discomfort—Etoposide—uterine cancer	0.000117	0.00107	CcSEcCtD
Triamcinolone—Hypersensitivity—Dactinomycin—uterine cancer	0.000116	0.00106	CcSEcCtD
Triamcinolone—Muscular weakness—Epirubicin—uterine cancer	0.000114	0.00105	CcSEcCtD
Triamcinolone—Cardiac arrest—Doxorubicin—uterine cancer	0.000114	0.00104	CcSEcCtD
Triamcinolone—Anaphylactic shock—Etoposide—uterine cancer	0.000114	0.00104	CcSEcCtD
Triamcinolone—Mood swings—Doxorubicin—uterine cancer	0.000114	0.00104	CcSEcCtD
Triamcinolone—Infection—Etoposide—uterine cancer	0.000113	0.00103	CcSEcCtD
Triamcinolone—Abdominal distension—Epirubicin—uterine cancer	0.000113	0.00103	CcSEcCtD
Triamcinolone—Asthenia—Dactinomycin—uterine cancer	0.000113	0.00103	CcSEcCtD
Triamcinolone—Asthma—Epirubicin—uterine cancer	0.000112	0.00103	CcSEcCtD
Triamcinolone—Influenza—Epirubicin—uterine cancer	0.000112	0.00103	CcSEcCtD
Triamcinolone—Tachycardia—Etoposide—uterine cancer	0.000111	0.00102	CcSEcCtD
Triamcinolone—CYP3A4—Benzo(a)pyrene metabolism—AKR1C3—uterine cancer	0.00011	0.024	CbGpPWpGaD
Triamcinolone—Hyperhidrosis—Etoposide—uterine cancer	0.00011	0.00101	CcSEcCtD
Triamcinolone—Pancreatitis—Epirubicin—uterine cancer	0.00011	0.00101	CcSEcCtD
Triamcinolone—Bronchitis—Epirubicin—uterine cancer	0.000108	0.000987	CcSEcCtD
Triamcinolone—Muscular weakness—Doxorubicin—uterine cancer	0.000106	0.000969	CcSEcCtD
Triamcinolone—Abdominal distension—Doxorubicin—uterine cancer	0.000104	0.000956	CcSEcCtD
Triamcinolone—Upper respiratory tract infection—Epirubicin—uterine cancer	0.000104	0.000954	CcSEcCtD
Triamcinolone—Influenza—Doxorubicin—uterine cancer	0.000104	0.000949	CcSEcCtD
Triamcinolone—Asthma—Doxorubicin—uterine cancer	0.000104	0.000949	CcSEcCtD
Triamcinolone—NR3C1—Nuclear Receptors—PGR—uterine cancer	0.000103	0.0223	CbGpPWpGaD
Triamcinolone—PTGS2—Prostaglandin Synthesis and Regulation—CYP11A1—uterine cancer	0.000102	0.0222	CbGpPWpGaD
Triamcinolone—Paraesthesia—Etoposide—uterine cancer	0.000102	0.000935	CcSEcCtD
Triamcinolone—Weight increased—Epirubicin—uterine cancer	0.000102	0.000934	CcSEcCtD
Triamcinolone—Pancreatitis—Doxorubicin—uterine cancer	0.000102	0.000931	CcSEcCtD
Triamcinolone—Dyspnoea—Etoposide—uterine cancer	0.000101	0.000928	CcSEcCtD
Triamcinolone—Vomiting—Dactinomycin—uterine cancer	9.98e-05	0.000915	CcSEcCtD
Triamcinolone—Bronchitis—Doxorubicin—uterine cancer	9.96e-05	0.000913	CcSEcCtD
Triamcinolone—Rash—Dactinomycin—uterine cancer	9.89e-05	0.000907	CcSEcCtD
Triamcinolone—NR3C1—Signaling events mediated by HDAC Class II—YWHAE—uterine cancer	9.8e-05	0.0213	CbGpPWpGaD
Triamcinolone—Fatigue—Etoposide—uterine cancer	9.79e-05	0.000897	CcSEcCtD
Triamcinolone—Neuropathy peripheral—Epirubicin—uterine cancer	9.78e-05	0.000897	CcSEcCtD
Triamcinolone—Pain—Etoposide—uterine cancer	9.71e-05	0.00089	CcSEcCtD
Triamcinolone—Conjunctivitis—Epirubicin—uterine cancer	9.7e-05	0.000889	CcSEcCtD
Triamcinolone—Upper respiratory tract infection—Doxorubicin—uterine cancer	9.63e-05	0.000882	CcSEcCtD
Triamcinolone—NR3C1—Endoderm Differentiation—HNF1B—uterine cancer	9.54e-05	0.0207	CbGpPWpGaD
Triamcinolone—Weight increased—Doxorubicin—uterine cancer	9.43e-05	0.000864	CcSEcCtD
Triamcinolone—Epistaxis—Epirubicin—uterine cancer	9.41e-05	0.000863	CcSEcCtD
Triamcinolone—Feeling abnormal—Etoposide—uterine cancer	9.36e-05	0.000858	CcSEcCtD
Triamcinolone—Nausea—Dactinomycin—uterine cancer	9.32e-05	0.000854	CcSEcCtD
Triamcinolone—Bradycardia—Epirubicin—uterine cancer	9.12e-05	0.000836	CcSEcCtD
Triamcinolone—Neuropathy peripheral—Doxorubicin—uterine cancer	9.05e-05	0.00083	CcSEcCtD
Triamcinolone—NR3C1—Nuclear Receptors—ESR2—uterine cancer	9.04e-05	0.0196	CbGpPWpGaD
Triamcinolone—Urticaria—Etoposide—uterine cancer	9.02e-05	0.000827	CcSEcCtD
Triamcinolone—Haemoglobin—Epirubicin—uterine cancer	9.01e-05	0.000826	CcSEcCtD
Triamcinolone—Rhinitis—Epirubicin—uterine cancer	8.98e-05	0.000823	CcSEcCtD
Triamcinolone—Body temperature increased—Etoposide—uterine cancer	8.98e-05	0.000823	CcSEcCtD
Triamcinolone—Conjunctivitis—Doxorubicin—uterine cancer	8.98e-05	0.000823	CcSEcCtD
Triamcinolone—Haemorrhage—Epirubicin—uterine cancer	8.96e-05	0.000821	CcSEcCtD
Triamcinolone—Pharyngitis—Epirubicin—uterine cancer	8.89e-05	0.000815	CcSEcCtD
Triamcinolone—BCHE—Peptide hormone metabolism—INHBA—uterine cancer	8.79e-05	0.0191	CbGpPWpGaD
Triamcinolone—Epistaxis—Doxorubicin—uterine cancer	8.71e-05	0.000798	CcSEcCtD
Triamcinolone—Bradycardia—Doxorubicin—uterine cancer	8.44e-05	0.000774	CcSEcCtD
Triamcinolone—Hypersensitivity—Etoposide—uterine cancer	8.37e-05	0.000767	CcSEcCtD
Triamcinolone—Haemoglobin—Doxorubicin—uterine cancer	8.33e-05	0.000764	CcSEcCtD
Triamcinolone—Rhinitis—Doxorubicin—uterine cancer	8.31e-05	0.000762	CcSEcCtD
Triamcinolone—Haemorrhage—Doxorubicin—uterine cancer	8.29e-05	0.00076	CcSEcCtD
Triamcinolone—BCHE—Peptide hormone metabolism—MME—uterine cancer	8.26e-05	0.018	CbGpPWpGaD
Triamcinolone—Pharyngitis—Doxorubicin—uterine cancer	8.23e-05	0.000754	CcSEcCtD
Triamcinolone—PTGS2—Aryl Hydrocarbon Receptor—NFE2L2—uterine cancer	8.19e-05	0.0178	CbGpPWpGaD
Triamcinolone—Asthenia—Etoposide—uterine cancer	8.15e-05	0.000747	CcSEcCtD
Triamcinolone—NR3C1—Nuclear Receptor transcription pathway—PGR—uterine cancer	8.11e-05	0.0176	CbGpPWpGaD
Triamcinolone—Pruritus—Etoposide—uterine cancer	8.03e-05	0.000736	CcSEcCtD
Triamcinolone—Arrhythmia—Epirubicin—uterine cancer	8e-05	0.000734	CcSEcCtD
Triamcinolone—Erythema—Epirubicin—uterine cancer	7.8e-05	0.000715	CcSEcCtD
Triamcinolone—Dysgeusia—Epirubicin—uterine cancer	7.64e-05	0.0007	CcSEcCtD
Triamcinolone—Back pain—Epirubicin—uterine cancer	7.55e-05	0.000692	CcSEcCtD
Triamcinolone—Dizziness—Etoposide—uterine cancer	7.51e-05	0.000688	CcSEcCtD
Triamcinolone—Arrhythmia—Doxorubicin—uterine cancer	7.41e-05	0.000679	CcSEcCtD
Triamcinolone—Ill-defined disorder—Epirubicin—uterine cancer	7.24e-05	0.000663	CcSEcCtD
Triamcinolone—Vomiting—Etoposide—uterine cancer	7.22e-05	0.000662	CcSEcCtD
Triamcinolone—Erythema—Doxorubicin—uterine cancer	7.22e-05	0.000662	CcSEcCtD
Triamcinolone—Rash—Etoposide—uterine cancer	7.16e-05	0.000656	CcSEcCtD
Triamcinolone—Dermatitis—Etoposide—uterine cancer	7.15e-05	0.000656	CcSEcCtD
Triamcinolone—NR3C1—Nuclear Receptor transcription pathway—ESR2—uterine cancer	7.14e-05	0.0155	CbGpPWpGaD
Triamcinolone—Headache—Etoposide—uterine cancer	7.11e-05	0.000652	CcSEcCtD
Triamcinolone—Dysgeusia—Doxorubicin—uterine cancer	7.07e-05	0.000648	CcSEcCtD
Triamcinolone—Malaise—Epirubicin—uterine cancer	7.03e-05	0.000645	CcSEcCtD
Triamcinolone—Vertigo—Epirubicin—uterine cancer	7.01e-05	0.000642	CcSEcCtD
Triamcinolone—Syncope—Epirubicin—uterine cancer	7e-05	0.000641	CcSEcCtD
Triamcinolone—Back pain—Doxorubicin—uterine cancer	6.98e-05	0.00064	CcSEcCtD
Triamcinolone—Loss of consciousness—Epirubicin—uterine cancer	6.86e-05	0.000628	CcSEcCtD
Triamcinolone—Cough—Epirubicin—uterine cancer	6.81e-05	0.000624	CcSEcCtD
Triamcinolone—Convulsion—Epirubicin—uterine cancer	6.76e-05	0.000619	CcSEcCtD
Triamcinolone—Nausea—Etoposide—uterine cancer	6.75e-05	0.000618	CcSEcCtD
Triamcinolone—Hypertension—Epirubicin—uterine cancer	6.73e-05	0.000617	CcSEcCtD
Triamcinolone—Ill-defined disorder—Doxorubicin—uterine cancer	6.7e-05	0.000614	CcSEcCtD
Triamcinolone—Myalgia—Epirubicin—uterine cancer	6.64e-05	0.000609	CcSEcCtD
Triamcinolone—Discomfort—Epirubicin—uterine cancer	6.56e-05	0.000601	CcSEcCtD
Triamcinolone—Malaise—Doxorubicin—uterine cancer	6.51e-05	0.000597	CcSEcCtD
Triamcinolone—Dry mouth—Epirubicin—uterine cancer	6.49e-05	0.000595	CcSEcCtD
Triamcinolone—Vertigo—Doxorubicin—uterine cancer	6.48e-05	0.000594	CcSEcCtD
Triamcinolone—Syncope—Doxorubicin—uterine cancer	6.47e-05	0.000593	CcSEcCtD
Triamcinolone—PTGS2—Arachidonic acid metabolism—AKR1C3—uterine cancer	6.41e-05	0.0139	CbGpPWpGaD
Triamcinolone—Anaphylactic shock—Epirubicin—uterine cancer	6.37e-05	0.000584	CcSEcCtD
Triamcinolone—Oedema—Epirubicin—uterine cancer	6.37e-05	0.000584	CcSEcCtD
Triamcinolone—Loss of consciousness—Doxorubicin—uterine cancer	6.34e-05	0.000581	CcSEcCtD
Triamcinolone—Infection—Epirubicin—uterine cancer	6.32e-05	0.00058	CcSEcCtD
Triamcinolone—Cough—Doxorubicin—uterine cancer	6.3e-05	0.000577	CcSEcCtD
Triamcinolone—Shock—Epirubicin—uterine cancer	6.26e-05	0.000574	CcSEcCtD
Triamcinolone—Convulsion—Doxorubicin—uterine cancer	6.25e-05	0.000573	CcSEcCtD
Triamcinolone—Hypertension—Doxorubicin—uterine cancer	6.23e-05	0.000571	CcSEcCtD
Triamcinolone—Tachycardia—Epirubicin—uterine cancer	6.21e-05	0.00057	CcSEcCtD
Triamcinolone—Hyperhidrosis—Epirubicin—uterine cancer	6.15e-05	0.000564	CcSEcCtD
Triamcinolone—Myalgia—Doxorubicin—uterine cancer	6.14e-05	0.000563	CcSEcCtD
Triamcinolone—NR3C1—Endoderm Differentiation—EZH2—uterine cancer	6.12e-05	0.0133	CbGpPWpGaD
Triamcinolone—Discomfort—Doxorubicin—uterine cancer	6.07e-05	0.000556	CcSEcCtD
Triamcinolone—Dry mouth—Doxorubicin—uterine cancer	6.01e-05	0.000551	CcSEcCtD
Triamcinolone—Oedema—Doxorubicin—uterine cancer	5.89e-05	0.00054	CcSEcCtD
Triamcinolone—Anaphylactic shock—Doxorubicin—uterine cancer	5.89e-05	0.00054	CcSEcCtD
Triamcinolone—Infection—Doxorubicin—uterine cancer	5.85e-05	0.000536	CcSEcCtD
Triamcinolone—Musculoskeletal discomfort—Epirubicin—uterine cancer	5.8e-05	0.000532	CcSEcCtD
Triamcinolone—Shock—Doxorubicin—uterine cancer	5.8e-05	0.000531	CcSEcCtD
Triamcinolone—Insomnia—Epirubicin—uterine cancer	5.76e-05	0.000528	CcSEcCtD
Triamcinolone—Tachycardia—Doxorubicin—uterine cancer	5.75e-05	0.000527	CcSEcCtD
Triamcinolone—Paraesthesia—Epirubicin—uterine cancer	5.72e-05	0.000524	CcSEcCtD
Triamcinolone—Hyperhidrosis—Doxorubicin—uterine cancer	5.69e-05	0.000522	CcSEcCtD
Triamcinolone—Dyspnoea—Epirubicin—uterine cancer	5.68e-05	0.00052	CcSEcCtD
Triamcinolone—PTGS2—Integrated Pancreatic Cancer Pathway—MAP3K4—uterine cancer	5.67e-05	0.0123	CbGpPWpGaD
Triamcinolone—NR3C1—Glucocorticoid receptor regulatory network—IRF1—uterine cancer	5.66e-05	0.0123	CbGpPWpGaD
Triamcinolone—Dyspepsia—Epirubicin—uterine cancer	5.6e-05	0.000514	CcSEcCtD
Triamcinolone—Fatigue—Epirubicin—uterine cancer	5.49e-05	0.000503	CcSEcCtD
Triamcinolone—NR3C1—Signaling events mediated by HDAC Class II—ESR1—uterine cancer	5.48e-05	0.0119	CbGpPWpGaD
Triamcinolone—NR3C1—Nuclear Receptors—ESR1—uterine cancer	5.48e-05	0.0119	CbGpPWpGaD
Triamcinolone—Pain—Epirubicin—uterine cancer	5.44e-05	0.000499	CcSEcCtD
Triamcinolone—Musculoskeletal discomfort—Doxorubicin—uterine cancer	5.37e-05	0.000492	CcSEcCtD
Triamcinolone—Insomnia—Doxorubicin—uterine cancer	5.33e-05	0.000488	CcSEcCtD
Triamcinolone—Paraesthesia—Doxorubicin—uterine cancer	5.29e-05	0.000485	CcSEcCtD
Triamcinolone—Dyspnoea—Doxorubicin—uterine cancer	5.25e-05	0.000481	CcSEcCtD
Triamcinolone—Feeling abnormal—Epirubicin—uterine cancer	5.25e-05	0.000481	CcSEcCtD
Triamcinolone—Dyspepsia—Doxorubicin—uterine cancer	5.19e-05	0.000475	CcSEcCtD
Triamcinolone—Fatigue—Doxorubicin—uterine cancer	5.08e-05	0.000465	CcSEcCtD
Triamcinolone—Urticaria—Epirubicin—uterine cancer	5.06e-05	0.000464	CcSEcCtD
Triamcinolone—Pain—Doxorubicin—uterine cancer	5.04e-05	0.000462	CcSEcCtD
Triamcinolone—PTGS2—Overview of nanoparticle effects—CXCL8—uterine cancer	5.04e-05	0.0109	CbGpPWpGaD
Triamcinolone—Body temperature increased—Epirubicin—uterine cancer	5.03e-05	0.000461	CcSEcCtD
Triamcinolone—Feeling abnormal—Doxorubicin—uterine cancer	4.85e-05	0.000445	CcSEcCtD
Triamcinolone—PTGS2—Quercetin and Nf-kB/ AP-1 Induced Cell Apoptosis—VEGFA—uterine cancer	4.69e-05	0.0102	CbGpPWpGaD
Triamcinolone—Hypersensitivity—Epirubicin—uterine cancer	4.69e-05	0.00043	CcSEcCtD
Triamcinolone—Urticaria—Doxorubicin—uterine cancer	4.68e-05	0.000429	CcSEcCtD
Triamcinolone—Body temperature increased—Doxorubicin—uterine cancer	4.66e-05	0.000427	CcSEcCtD
Triamcinolone—PTGS2—Selenium Micronutrient Network—GPX3—uterine cancer	4.65e-05	0.0101	CbGpPWpGaD
Triamcinolone—Asthenia—Epirubicin—uterine cancer	4.57e-05	0.000419	CcSEcCtD
Triamcinolone—Pruritus—Epirubicin—uterine cancer	4.5e-05	0.000413	CcSEcCtD
Triamcinolone—PTGS2—Signaling mediated by p38-alpha and p38-beta—ESR1—uterine cancer	4.44e-05	0.00964	CbGpPWpGaD
Triamcinolone—Hypersensitivity—Doxorubicin—uterine cancer	4.34e-05	0.000398	CcSEcCtD
Triamcinolone—NR3C1—Nuclear Receptor transcription pathway—ESR1—uterine cancer	4.33e-05	0.00942	CbGpPWpGaD
Triamcinolone—Asthenia—Doxorubicin—uterine cancer	4.23e-05	0.000387	CcSEcCtD
Triamcinolone—NR3C1—Endoderm Differentiation—SMAD3—uterine cancer	4.22e-05	0.00917	CbGpPWpGaD
Triamcinolone—Dizziness—Epirubicin—uterine cancer	4.21e-05	0.000386	CcSEcCtD
Triamcinolone—Pruritus—Doxorubicin—uterine cancer	4.17e-05	0.000382	CcSEcCtD
Triamcinolone—BCHE—Neuronal System—ABCC9—uterine cancer	4.17e-05	0.00905	CbGpPWpGaD
Triamcinolone—PTGS2—S1P1 pathway—VEGFA—uterine cancer	4.09e-05	0.00889	CbGpPWpGaD
Triamcinolone—Vomiting—Epirubicin—uterine cancer	4.05e-05	0.000371	CcSEcCtD
Triamcinolone—NR3C1—Regulation of nuclear SMAD2/3 signaling—CDKN2B—uterine cancer	4.02e-05	0.00873	CbGpPWpGaD
Triamcinolone—Rash—Epirubicin—uterine cancer	4.01e-05	0.000368	CcSEcCtD
Triamcinolone—Dermatitis—Epirubicin—uterine cancer	4.01e-05	0.000368	CcSEcCtD
Triamcinolone—Headache—Epirubicin—uterine cancer	3.99e-05	0.000366	CcSEcCtD
Triamcinolone—Dizziness—Doxorubicin—uterine cancer	3.9e-05	0.000357	CcSEcCtD
Triamcinolone—NR3C1—Adipogenesis—HMGA1—uterine cancer	3.84e-05	0.00834	CbGpPWpGaD
Triamcinolone—Nausea—Epirubicin—uterine cancer	3.78e-05	0.000347	CcSEcCtD
Triamcinolone—Vomiting—Doxorubicin—uterine cancer	3.75e-05	0.000343	CcSEcCtD
Triamcinolone—BCHE—Metabolism of proteins—TSPYL2—uterine cancer	3.72e-05	0.00807	CbGpPWpGaD
Triamcinolone—Rash—Doxorubicin—uterine cancer	3.71e-05	0.00034	CcSEcCtD
Triamcinolone—Dermatitis—Doxorubicin—uterine cancer	3.71e-05	0.00034	CcSEcCtD
Triamcinolone—Headache—Doxorubicin—uterine cancer	3.69e-05	0.000338	CcSEcCtD
Triamcinolone—NR3C1—Regulation of nuclear SMAD2/3 signaling—SMAD3—uterine cancer	3.67e-05	0.00797	CbGpPWpGaD
Triamcinolone—PTGS2—Aryl Hydrocarbon Receptor—ESR1—uterine cancer	3.57e-05	0.00775	CbGpPWpGaD
Triamcinolone—Nausea—Doxorubicin—uterine cancer	3.5e-05	0.000321	CcSEcCtD
Triamcinolone—NR3C1—AP-1 transcription factor network—ESR1—uterine cancer	3.36e-05	0.00731	CbGpPWpGaD
Triamcinolone—NR3C1—BMAL1:CLOCK,NPAS2 activates circadian gene expression—EP300—uterine cancer	3.34e-05	0.00726	CbGpPWpGaD
Triamcinolone—BCHE—Metabolism of lipids and lipoproteins—SRD5A2—uterine cancer	3.26e-05	0.00708	CbGpPWpGaD
Triamcinolone—PTGS2—Integrated Pancreatic Cancer Pathway—INHBA—uterine cancer	3.17e-05	0.00688	CbGpPWpGaD
Triamcinolone—NR3C1—SIDS Susceptibility Pathways—YWHAE—uterine cancer	3.16e-05	0.00688	CbGpPWpGaD
Triamcinolone—NR3C1—Regulation of nuclear SMAD2/3 signaling—ESR1—uterine cancer	2.99e-05	0.0065	CbGpPWpGaD
Triamcinolone—NR3C1—AP-1 transcription factor network—CCL2—uterine cancer	2.96e-05	0.00643	CbGpPWpGaD
Triamcinolone—NR3C1—SIDS Susceptibility Pathways—ESR2—uterine cancer	2.92e-05	0.00635	CbGpPWpGaD
Triamcinolone—NR3C1—Adipogenesis—SOCS3—uterine cancer	2.87e-05	0.00624	CbGpPWpGaD
Triamcinolone—NR3C1—AP-1 transcription factor network—CDKN2A—uterine cancer	2.58e-05	0.00561	CbGpPWpGaD
Triamcinolone—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP11A1—uterine cancer	2.56e-05	0.00557	CbGpPWpGaD
Triamcinolone—CYP3A4—Oxidation by Cytochrome P450—CYP11A1—uterine cancer	2.53e-05	0.0055	CbGpPWpGaD
Triamcinolone—NR3C1—Adipogenesis—SMAD3—uterine cancer	2.51e-05	0.00546	CbGpPWpGaD
Triamcinolone—NR3C1—Regulation of Androgen receptor activity—EP300—uterine cancer	2.51e-05	0.00545	CbGpPWpGaD
Triamcinolone—NR3C1—Circadian Clock—EP300—uterine cancer	2.43e-05	0.00529	CbGpPWpGaD
Triamcinolone—PTGS2—Aryl Hydrocarbon Receptor—CDKN1B—uterine cancer	2.42e-05	0.00527	CbGpPWpGaD
Triamcinolone—PTGS2—Defective AMN causes hereditary megaloblastic anemia 1—MTHFR—uterine cancer	2.41e-05	0.00524	CbGpPWpGaD
Triamcinolone—PTGS2—Selenium Micronutrient Network—MTHFR—uterine cancer	2.39e-05	0.00519	CbGpPWpGaD
Triamcinolone—BCHE—Metabolism of lipids and lipoproteins—STAR—uterine cancer	2.36e-05	0.00512	CbGpPWpGaD
Triamcinolone—BCHE—Metabolism of lipids and lipoproteins—AKR1B1—uterine cancer	2.36e-05	0.00512	CbGpPWpGaD
Triamcinolone—NR3C1—AP-1 transcription factor network—CXCL8—uterine cancer	2.34e-05	0.00509	CbGpPWpGaD
Triamcinolone—CYP3A4—Tryptophan metabolism—CYP19A1—uterine cancer	2.33e-05	0.00507	CbGpPWpGaD
Triamcinolone—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—CXCL8—uterine cancer	2.32e-05	0.00505	CbGpPWpGaD
Triamcinolone—NR3C1—AP-1 transcription factor network—CDKN1B—uterine cancer	2.29e-05	0.00497	CbGpPWpGaD
Triamcinolone—PTGS2—Metabolism of lipids and lipoproteins—SRD5A2—uterine cancer	2.24e-05	0.00487	CbGpPWpGaD
Triamcinolone—NR3C1—Endoderm Differentiation—CTNNB1—uterine cancer	2.21e-05	0.0048	CbGpPWpGaD
Triamcinolone—NR3C1—AP-1 transcription factor network—CTNNB1—uterine cancer	2.16e-05	0.00469	CbGpPWpGaD
Triamcinolone—PTGS2—Aryl Hydrocarbon Receptor—EP300—uterine cancer	2.13e-05	0.00463	CbGpPWpGaD
Triamcinolone—NR3C1—AP-1 transcription factor network—PTEN—uterine cancer	2.1e-05	0.00457	CbGpPWpGaD
Triamcinolone—CYP3A4—Phase 1 - Functionalization of compounds—CYP11A1—uterine cancer	2.08e-05	0.00451	CbGpPWpGaD
Triamcinolone—NR3C1—Glucocorticoid receptor regulatory network—CXCL8—uterine cancer	2.06e-05	0.00448	CbGpPWpGaD
Triamcinolone—BCHE—Peptide hormone metabolism—CTNNB1—uterine cancer	2.04e-05	0.00442	CbGpPWpGaD
Triamcinolone—PTGS2—Integrated Pancreatic Cancer Pathway—EZH2—uterine cancer	2.03e-05	0.00441	CbGpPWpGaD
Triamcinolone—PTGS2—Aryl Hydrocarbon Receptor—VEGFA—uterine cancer	2.02e-05	0.00438	CbGpPWpGaD
Triamcinolone—NR3C1—AP-1 transcription factor network—EP300—uterine cancer	2.01e-05	0.00436	CbGpPWpGaD
Triamcinolone—PTGS2—Aryl Hydrocarbon Receptor—NRAS—uterine cancer	1.99e-05	0.00433	CbGpPWpGaD
Triamcinolone—CYP3A4—Metapathway biotransformation—AKR1B10—uterine cancer	1.96e-05	0.00425	CbGpPWpGaD
Triamcinolone—NR3C1—Gene Expression—PHF1—uterine cancer	1.9e-05	0.00413	CbGpPWpGaD
Triamcinolone—PTGS2—Signaling mediated by p38-alpha and p38-beta—TP53—uterine cancer	1.9e-05	0.00412	CbGpPWpGaD
Triamcinolone—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP19A1—uterine cancer	1.89e-05	0.0041	CbGpPWpGaD
Triamcinolone—PTGS2—Integrated Pancreatic Cancer Pathway—ESR2—uterine cancer	1.88e-05	0.00409	CbGpPWpGaD
Triamcinolone—PTGS2—Selenium Micronutrient Network—CCL2—uterine cancer	1.87e-05	0.00406	CbGpPWpGaD
Triamcinolone—CYP3A4—Oxidation by Cytochrome P450—CYP19A1—uterine cancer	1.86e-05	0.00404	CbGpPWpGaD
Triamcinolone—CYP3A4—Metapathway biotransformation—AKR1B1—uterine cancer	1.82e-05	0.00395	CbGpPWpGaD
Triamcinolone—NR3C1—Regulation of nuclear SMAD2/3 signaling—EP300—uterine cancer	1.79e-05	0.00388	CbGpPWpGaD
Triamcinolone—NR3C1—Glucocorticoid receptor regulatory network—EP300—uterine cancer	1.77e-05	0.00384	CbGpPWpGaD
Triamcinolone—NR3C1—FOXA2 and FOXA3 transcription factor networks—AKT1—uterine cancer	1.76e-05	0.00382	CbGpPWpGaD
Triamcinolone—BCHE—Metabolism of lipids and lipoproteins—AKR1C1—uterine cancer	1.73e-05	0.00376	CbGpPWpGaD
Triamcinolone—PTGS2—Aryl Hydrocarbon Receptor—KRAS—uterine cancer	1.71e-05	0.00372	CbGpPWpGaD
Triamcinolone—PTGS2—Integrated Pancreatic Cancer Pathway—STK11—uterine cancer	1.71e-05	0.00371	CbGpPWpGaD
Triamcinolone—PTGS2—C-MYB transcription factor network—CDKN2A—uterine cancer	1.69e-05	0.00367	CbGpPWpGaD
Triamcinolone—BCHE—Metabolism of proteins—INHBA—uterine cancer	1.66e-05	0.00361	CbGpPWpGaD
Triamcinolone—PTGS2—Metabolism of lipids and lipoproteins—STAR—uterine cancer	1.62e-05	0.00352	CbGpPWpGaD
Triamcinolone—PTGS2—Metabolism of lipids and lipoproteins—AKR1B1—uterine cancer	1.62e-05	0.00352	CbGpPWpGaD
Triamcinolone—NR3C1—Gene Expression—CHD4—uterine cancer	1.62e-05	0.00351	CbGpPWpGaD
Triamcinolone—BCHE—Metabolism of proteins—MME—uterine cancer	1.56e-05	0.00339	CbGpPWpGaD
Triamcinolone—PTGS2—Integrated Pancreatic Cancer Pathway—CDKN2B—uterine cancer	1.53e-05	0.00333	CbGpPWpGaD
Triamcinolone—CYP3A4—Phase 1 - Functionalization of compounds—CYP19A1—uterine cancer	1.53e-05	0.00332	CbGpPWpGaD
Triamcinolone—PTGS2—C-MYB transcription factor network—CDKN1B—uterine cancer	1.5e-05	0.00325	CbGpPWpGaD
Triamcinolone—PTGS2—Spinal Cord Injury—CCL2—uterine cancer	1.48e-05	0.00321	CbGpPWpGaD
Triamcinolone—PTGS2—Aryl Hydrocarbon Receptor—HRAS—uterine cancer	1.46e-05	0.00317	CbGpPWpGaD
Triamcinolone—BCHE—Metabolism—SRD5A2—uterine cancer	1.45e-05	0.00315	CbGpPWpGaD
Triamcinolone—BCHE—Metabolism—NDUFB11—uterine cancer	1.45e-05	0.00315	CbGpPWpGaD
Triamcinolone—NR3C1—AP-1 transcription factor network—TP53—uterine cancer	1.44e-05	0.00312	CbGpPWpGaD
Triamcinolone—BCHE—Metabolism of lipids and lipoproteins—CYP11A1—uterine cancer	1.41e-05	0.00306	CbGpPWpGaD
Triamcinolone—NR3C1—Generic Transcription Pathway—PGR—uterine cancer	1.4e-05	0.00305	CbGpPWpGaD
Triamcinolone—NR3C1—Gene Expression—SUZ12—uterine cancer	1.36e-05	0.00294	CbGpPWpGaD
Triamcinolone—BCHE—Phospholipid metabolism—PTEN—uterine cancer	1.35e-05	0.00293	CbGpPWpGaD
Triamcinolone—CYP3A4—Metapathway biotransformation—AKR1C1—uterine cancer	1.34e-05	0.0029	CbGpPWpGaD
Triamcinolone—BCHE—Metabolism of lipids and lipoproteins—AKR1C3—uterine cancer	1.33e-05	0.00289	CbGpPWpGaD
Triamcinolone—NR3C1—Adipogenesis—CTNNB1—uterine cancer	1.32e-05	0.00286	CbGpPWpGaD
Triamcinolone—PTGS2—C-MYB transcription factor network—EP300—uterine cancer	1.31e-05	0.00286	CbGpPWpGaD
Triamcinolone—NR3C1—Glucocorticoid receptor regulatory network—TP53—uterine cancer	1.27e-05	0.00275	CbGpPWpGaD
Triamcinolone—NR3C1—Generic Transcription Pathway—ESR2—uterine cancer	1.23e-05	0.00268	CbGpPWpGaD
Triamcinolone—NR3C1—SIDS Susceptibility Pathways—CXCL8—uterine cancer	1.23e-05	0.00268	CbGpPWpGaD
Triamcinolone—PTGS2—C-MYB transcription factor network—NRAS—uterine cancer	1.23e-05	0.00267	CbGpPWpGaD
Triamcinolone—PTGS2—Metabolism of lipids and lipoproteins—AKR1C1—uterine cancer	1.19e-05	0.00259	CbGpPWpGaD
Triamcinolone—CYP3A4—Metapathway biotransformation—GPX3—uterine cancer	1.17e-05	0.00255	CbGpPWpGaD
Triamcinolone—PTGS2—Spinal Cord Injury—CXCL8—uterine cancer	1.17e-05	0.00254	CbGpPWpGaD
Triamcinolone—PTGS2—Integrated Pancreatic Cancer Pathway—ESR1—uterine cancer	1.14e-05	0.00248	CbGpPWpGaD
Triamcinolone—PTGS2—Spinal Cord Injury—CDKN1B—uterine cancer	1.14e-05	0.00248	CbGpPWpGaD
Triamcinolone—NR3C1—SIDS Susceptibility Pathways—CTNNB1—uterine cancer	1.14e-05	0.00247	CbGpPWpGaD
Triamcinolone—CYP3A4—Biological oxidations—CYP11A1—uterine cancer	1.1e-05	0.0024	CbGpPWpGaD
Triamcinolone—CYP3A4—Metapathway biotransformation—CYP11A1—uterine cancer	1.09e-05	0.00237	CbGpPWpGaD
Triamcinolone—NR3C1—Regulation of nuclear SMAD2/3 signaling—AKT1—uterine cancer	1.08e-05	0.00235	CbGpPWpGaD
Triamcinolone—NR3C1—Glucocorticoid receptor regulatory network—AKT1—uterine cancer	1.07e-05	0.00232	CbGpPWpGaD
Triamcinolone—PTGS2—C-MYB transcription factor network—KRAS—uterine cancer	1.06e-05	0.0023	CbGpPWpGaD
Triamcinolone—NR3C1—SIDS Susceptibility Pathways—EP300—uterine cancer	1.06e-05	0.0023	CbGpPWpGaD
Triamcinolone—BCHE—Metabolism—AKR1B1—uterine cancer	1.05e-05	0.00228	CbGpPWpGaD
Triamcinolone—BCHE—Metabolism—STAR—uterine cancer	1.05e-05	0.00228	CbGpPWpGaD
Triamcinolone—BCHE—Metabolism of lipids and lipoproteins—CYP19A1—uterine cancer	1.04e-05	0.00225	CbGpPWpGaD
Triamcinolone—CYP3A4—Metapathway biotransformation—AKR1C3—uterine cancer	1.03e-05	0.00223	CbGpPWpGaD
Triamcinolone—BCHE—Metabolism of proteins—FBXW7—uterine cancer	1.03e-05	0.00223	CbGpPWpGaD
Triamcinolone—NR3C1—Generic Transcription Pathway—CDKN2B—uterine cancer	1e-05	0.00218	CbGpPWpGaD
Triamcinolone—NR3C1—SIDS Susceptibility Pathways—VEGFA—uterine cancer	1e-05	0.00218	CbGpPWpGaD
Triamcinolone—PTGS2—Metabolism—NDUFB11—uterine cancer	9.99e-06	0.00217	CbGpPWpGaD
Triamcinolone—PTGS2—Metabolism—SRD5A2—uterine cancer	9.99e-06	0.00217	CbGpPWpGaD
Triamcinolone—PTGS2—Metabolism of lipids and lipoproteins—CYP11A1—uterine cancer	9.7e-06	0.00211	CbGpPWpGaD
Triamcinolone—BCHE—Phospholipid metabolism—PIK3CA—uterine cancer	9.5e-06	0.00206	CbGpPWpGaD
Triamcinolone—PTGS2—Disease—AKR1B10—uterine cancer	9.28e-06	0.00202	CbGpPWpGaD
Triamcinolone—NR3C1—Generic Transcription Pathway—SMAD3—uterine cancer	9.17e-06	0.00199	CbGpPWpGaD
Triamcinolone—PTGS2—Metabolism of lipids and lipoproteins—AKR1C3—uterine cancer	9.16e-06	0.00199	CbGpPWpGaD
Triamcinolone—PTGS2—C-MYB transcription factor network—HRAS—uterine cancer	9e-06	0.00196	CbGpPWpGaD
Triamcinolone—PTGS2—Integrated Pancreatic Cancer Pathway—ERBB2—uterine cancer	8.38e-06	0.00182	CbGpPWpGaD
Triamcinolone—BCHE—Metabolism—POLD1—uterine cancer	8.23e-06	0.00179	CbGpPWpGaD
Triamcinolone—CYP3A4—Biological oxidations—CYP19A1—uterine cancer	8.12e-06	0.00176	CbGpPWpGaD
Triamcinolone—CYP3A4—Metapathway biotransformation—CYP19A1—uterine cancer	8.01e-06	0.00174	CbGpPWpGaD
Triamcinolone—PTGS2—Integrated Pancreatic Cancer Pathway—CDKN1B—uterine cancer	7.76e-06	0.00169	CbGpPWpGaD
Triamcinolone—BCHE—Metabolism—AKR1C1—uterine cancer	7.7e-06	0.00167	CbGpPWpGaD
Triamcinolone—PTGS2—Disease—RNF43—uterine cancer	7.69e-06	0.00167	CbGpPWpGaD
Triamcinolone—NR3C1—Generic Transcription Pathway—ESR1—uterine cancer	7.48e-06	0.00163	CbGpPWpGaD
Triamcinolone—PTGS2—Integrated Pancreatic Cancer Pathway—CTNNB1—uterine cancer	7.33e-06	0.00159	CbGpPWpGaD
Triamcinolone—PTGS2—Metabolism—AKR1B1—uterine cancer	7.22e-06	0.00157	CbGpPWpGaD
Triamcinolone—PTGS2—Metabolism—STAR—uterine cancer	7.22e-06	0.00157	CbGpPWpGaD
Triamcinolone—PTGS2—Spinal Cord Injury—TP53—uterine cancer	7.17e-06	0.00156	CbGpPWpGaD
Triamcinolone—PTGS2—Integrated Pancreatic Cancer Pathway—PTEN—uterine cancer	7.15e-06	0.00155	CbGpPWpGaD
Triamcinolone—PTGS2—Metabolism of lipids and lipoproteins—CYP19A1—uterine cancer	7.14e-06	0.00155	CbGpPWpGaD
Triamcinolone—BCHE—Metabolism—RRM2—uterine cancer	6.86e-06	0.00149	CbGpPWpGaD
Triamcinolone—PTGS2—Integrated Pancreatic Cancer Pathway—EP300—uterine cancer	6.82e-06	0.00148	CbGpPWpGaD
Triamcinolone—NR3C1—Gene Expression—PGR—uterine cancer	6.75e-06	0.00147	CbGpPWpGaD
Triamcinolone—BCHE—Metabolism—DCN—uterine cancer	6.66e-06	0.00145	CbGpPWpGaD
Triamcinolone—BCHE—Transmission across Chemical Synapses—HRAS—uterine cancer	6.53e-06	0.00142	CbGpPWpGaD
Triamcinolone—PTGS2—Integrated Pancreatic Cancer Pathway—VEGFA—uterine cancer	6.45e-06	0.0014	CbGpPWpGaD
Triamcinolone—NR3C1—Gene Expression—EZH2—uterine cancer	6.41e-06	0.00139	CbGpPWpGaD
Triamcinolone—PTGS2—Disease—AKR1C1—uterine cancer	6.33e-06	0.00138	CbGpPWpGaD
Triamcinolone—BCHE—Metabolism—CYP11A1—uterine cancer	6.28e-06	0.00136	CbGpPWpGaD
Triamcinolone—NR3C1—Gene Expression—ESR2—uterine cancer	5.94e-06	0.00129	CbGpPWpGaD
Triamcinolone—BCHE—Metabolism—AKR1C3—uterine cancer	5.93e-06	0.00129	CbGpPWpGaD
Triamcinolone—PTGS2—Metabolism—POLD1—uterine cancer	5.67e-06	0.00123	CbGpPWpGaD
Triamcinolone—PTGS2—Integrated Pancreatic Cancer Pathway—KRAS—uterine cancer	5.49e-06	0.00119	CbGpPWpGaD
Triamcinolone—PTGS2—Disease—DCN—uterine cancer	5.48e-06	0.00119	CbGpPWpGaD
Triamcinolone—PTGS2—Metabolism—AKR1C1—uterine cancer	5.3e-06	0.00115	CbGpPWpGaD
Triamcinolone—BCHE—Metabolism of proteins—CCL2—uterine cancer	5.27e-06	0.00115	CbGpPWpGaD
Triamcinolone—PTGS2—Integrated Pancreatic Cancer Pathway—PIK3CA—uterine cancer	5.04e-06	0.0011	CbGpPWpGaD
Triamcinolone—BCHE—Neuronal System—HRAS—uterine cancer	5e-06	0.00109	CbGpPWpGaD
Triamcinolone—PTGS2—Integrated Pancreatic Cancer Pathway—TP53—uterine cancer	4.88e-06	0.00106	CbGpPWpGaD
Triamcinolone—PTGS2—Disease—AKR1C3—uterine cancer	4.87e-06	0.00106	CbGpPWpGaD
Triamcinolone—NR3C1—Gene Expression—CDKN2B—uterine cancer	4.84e-06	0.00105	CbGpPWpGaD
Triamcinolone—PTGS2—Disease—HMGA1—uterine cancer	4.75e-06	0.00103	CbGpPWpGaD
Triamcinolone—PTGS2—Metabolism—RRM2—uterine cancer	4.72e-06	0.00103	CbGpPWpGaD
Triamcinolone—BCHE—Metabolism—STK11—uterine cancer	4.62e-06	0.001	CbGpPWpGaD
Triamcinolone—BCHE—Metabolism—CYP19A1—uterine cancer	4.62e-06	0.001	CbGpPWpGaD
Triamcinolone—PTGS2—Metabolism—DCN—uterine cancer	4.59e-06	0.000997	CbGpPWpGaD
Triamcinolone—NR3C1—Gene Expression—SMAD3—uterine cancer	4.42e-06	0.00096	CbGpPWpGaD
Triamcinolone—CYP3A4—Metabolism—SRD5A2—uterine cancer	4.36e-06	0.000948	CbGpPWpGaD
Triamcinolone—CYP3A4—Metabolism—NDUFB11—uterine cancer	4.36e-06	0.000948	CbGpPWpGaD
Triamcinolone—PTGS2—Disease—FBXW7—uterine cancer	4.34e-06	0.000944	CbGpPWpGaD
Triamcinolone—BCHE—Metabolism of lipids and lipoproteins—PTEN—uterine cancer	4.34e-06	0.000942	CbGpPWpGaD
Triamcinolone—PTGS2—Metabolism—CYP11A1—uterine cancer	4.32e-06	0.000939	CbGpPWpGaD
Triamcinolone—BCHE—Metabolism of proteins—CXCL8—uterine cancer	4.17e-06	0.000905	CbGpPWpGaD
Triamcinolone—BCHE—Metabolism of lipids and lipoproteins—EP300—uterine cancer	4.13e-06	0.000898	CbGpPWpGaD
Triamcinolone—PTGS2—Integrated Pancreatic Cancer Pathway—AKT1—uterine cancer	4.12e-06	0.000895	CbGpPWpGaD
Triamcinolone—PTGS2—Metabolism—AKR1C3—uterine cancer	4.08e-06	0.000887	CbGpPWpGaD
Triamcinolone—BCHE—Metabolism of proteins—CTNNB1—uterine cancer	3.84e-06	0.000835	CbGpPWpGaD
Triamcinolone—NR3C1—Gene Expression—ESR1—uterine cancer	3.6e-06	0.000783	CbGpPWpGaD
Triamcinolone—BCHE—Metabolism—MTHFR—uterine cancer	3.47e-06	0.000754	CbGpPWpGaD
Triamcinolone—PTGS2—Disease—CDKN2B—uterine cancer	3.4e-06	0.000739	CbGpPWpGaD
Triamcinolone—PTGS2—Metabolism—STK11—uterine cancer	3.18e-06	0.000691	CbGpPWpGaD
Triamcinolone—PTGS2—Metabolism—CYP19A1—uterine cancer	3.18e-06	0.000691	CbGpPWpGaD
Triamcinolone—CYP3A4—Metabolism—AKR1B1—uterine cancer	3.15e-06	0.000685	CbGpPWpGaD
Triamcinolone—CYP3A4—Metabolism—STAR—uterine cancer	3.15e-06	0.000685	CbGpPWpGaD
Triamcinolone—PTGS2—Disease—SMAD3—uterine cancer	3.11e-06	0.000675	CbGpPWpGaD
Triamcinolone—BCHE—Metabolism of lipids and lipoproteins—PIK3CA—uterine cancer	3.06e-06	0.000665	CbGpPWpGaD
Triamcinolone—PTGS2—Metabolism of lipids and lipoproteins—PTEN—uterine cancer	2.98e-06	0.000648	CbGpPWpGaD
Triamcinolone—PTGS2—Disease—FGFR2—uterine cancer	2.96e-06	0.000644	CbGpPWpGaD
Triamcinolone—PTGS2—Disease—MTHFR—uterine cancer	2.85e-06	0.00062	CbGpPWpGaD
Triamcinolone—PTGS2—Metabolism of lipids and lipoproteins—EP300—uterine cancer	2.85e-06	0.000618	CbGpPWpGaD
Triamcinolone—CYP3A4—Metabolism—POLD1—uterine cancer	2.47e-06	0.000538	CbGpPWpGaD
Triamcinolone—PTGS2—Metabolism—MTHFR—uterine cancer	2.39e-06	0.000519	CbGpPWpGaD
Triamcinolone—CYP3A4—Metabolism—AKR1C1—uterine cancer	2.31e-06	0.000503	CbGpPWpGaD
Triamcinolone—PTGS2—Metabolism of lipids and lipoproteins—PIK3CA—uterine cancer	2.11e-06	0.000457	CbGpPWpGaD
Triamcinolone—CYP3A4—Metabolism—RRM2—uterine cancer	2.06e-06	0.000448	CbGpPWpGaD
Triamcinolone—CYP3A4—Metabolism—DCN—uterine cancer	2e-06	0.000435	CbGpPWpGaD
Triamcinolone—BCHE—Metabolism—PTEN—uterine cancer	1.93e-06	0.00042	CbGpPWpGaD
Triamcinolone—CYP3A4—Metabolism—CYP11A1—uterine cancer	1.89e-06	0.00041	CbGpPWpGaD
Triamcinolone—PTGS2—Disease—ERBB2—uterine cancer	1.86e-06	0.000404	CbGpPWpGaD
Triamcinolone—BCHE—Metabolism—EP300—uterine cancer	1.84e-06	0.0004	CbGpPWpGaD
Triamcinolone—CYP3A4—Metabolism—AKR1C3—uterine cancer	1.78e-06	0.000387	CbGpPWpGaD
Triamcinolone—PTGS2—Disease—CDKN1B—uterine cancer	1.72e-06	0.000375	CbGpPWpGaD
Triamcinolone—PTGS2—Disease—CTNNB1—uterine cancer	1.63e-06	0.000354	CbGpPWpGaD
Triamcinolone—PTGS2—Disease—PTEN—uterine cancer	1.59e-06	0.000345	CbGpPWpGaD
Triamcinolone—PTGS2—Disease—EP300—uterine cancer	1.51e-06	0.000329	CbGpPWpGaD
Triamcinolone—PTGS2—Disease—NRAS—uterine cancer	1.42e-06	0.000308	CbGpPWpGaD
Triamcinolone—CYP3A4—Metabolism—CYP19A1—uterine cancer	1.39e-06	0.000302	CbGpPWpGaD
Triamcinolone—CYP3A4—Metabolism—STK11—uterine cancer	1.39e-06	0.000302	CbGpPWpGaD
Triamcinolone—BCHE—Metabolism—PIK3CA—uterine cancer	1.36e-06	0.000296	CbGpPWpGaD
Triamcinolone—PTGS2—Metabolism—PTEN—uterine cancer	1.33e-06	0.000289	CbGpPWpGaD
Triamcinolone—NR3C1—Gene Expression—AKT1—uterine cancer	1.3e-06	0.000282	CbGpPWpGaD
Triamcinolone—PTGS2—Metabolism—EP300—uterine cancer	1.27e-06	0.000275	CbGpPWpGaD
Triamcinolone—PTGS2—Disease—KRAS—uterine cancer	1.22e-06	0.000265	CbGpPWpGaD
Triamcinolone—PTGS2—Disease—PIK3CA—uterine cancer	1.12e-06	0.000243	CbGpPWpGaD
Triamcinolone—BCHE—Metabolism—AKT1—uterine cancer	1.11e-06	0.000242	CbGpPWpGaD
Triamcinolone—CYP3A4—Metabolism—MTHFR—uterine cancer	1.04e-06	0.000227	CbGpPWpGaD
Triamcinolone—PTGS2—Disease—HRAS—uterine cancer	1.04e-06	0.000225	CbGpPWpGaD
Triamcinolone—PTGS2—Metabolism—PIK3CA—uterine cancer	9.38e-07	0.000204	CbGpPWpGaD
Triamcinolone—PTGS2—Disease—AKT1—uterine cancer	9.15e-07	0.000199	CbGpPWpGaD
Triamcinolone—PTGS2—Metabolism—AKT1—uterine cancer	7.66e-07	0.000166	CbGpPWpGaD
Triamcinolone—CYP3A4—Metabolism—PTEN—uterine cancer	5.8e-07	0.000126	CbGpPWpGaD
Triamcinolone—CYP3A4—Metabolism—EP300—uterine cancer	5.54e-07	0.00012	CbGpPWpGaD
Triamcinolone—CYP3A4—Metabolism—PIK3CA—uterine cancer	4.09e-07	8.9e-05	CbGpPWpGaD
Triamcinolone—CYP3A4—Metabolism—AKT1—uterine cancer	3.34e-07	7.27e-05	CbGpPWpGaD
